Neoral® rescue therapy in transplant patients with intolerance to tacrolimus

Clinical Transplantation

Volumn 16, Issue 3, 2002, Pages 168-172

  Abouljoud, Marwan S ^a   Kumar, Ms Anil ^b   Brayman, Kenneth L ^c   Emre, Sukru ^d   Bynon, J S ^e  

^a HENRY FORD HOSPITAL   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cyclosporine based immunosuppression; Immunosuppression; Intolerance to calcineurin inhibitors; Rescue therapy in transplant patients; Tacrolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORINE MICROEMULSION; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; ACUTE DISEASE; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT REJECTION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MICROEMULSION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 0036304085     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2002.01054.x     Document Type: Article

References (16)

1. Neoral use in the liver transplant recipient
2. Neoral use in the renal transplant recipient
3. Neoral use in the cardiac transplant recipient
4. Cyclosporine
5. Cyclosporine: A revolution in transplantation
6. Cyclosporine: The principal immunosuppressant for renal transplantation
7. Improved graft survival after renal transplantation in the United States, 1988 to 1996
8. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone
9. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients
10. Nephrotoxicity following orthotopic liver transplantation: A comparison between cyclosporine and FK506
11. Gastrointestinal toxicity associated with FK506 in liver transplant recipients
12. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients
13. Conversion to Neoral for neurotoxicity after primary adult liver transplantation under tacrolimus
14. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression
15. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: Safety, metabolic changes, and pharmacokinetic comparison
16. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: A single center experience